Nap B.V. Forgrowth Sells 29,846 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 29,846 shares of the company’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $25.54, for a total value of $762,266.84. Following the sale, the insider now owns 10,656,172 shares of the company’s stock, valued at $272,158,632.88. This trade represents a 0.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Thursday, December 26th, Nap B.V. Forgrowth sold 33,438 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $26.01, for a total transaction of $869,722.38.
• On Monday, December 23rd, Nap B.V. Forgrowth sold 25,132 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.49, for a total transaction of $640,614.68.
• On Friday, December 20th, Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.60, for a total transaction of $1,274,163.20.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $26.10, for a total transaction of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.39, for a total value of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total value of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.02, for a total value of $213,420.60.

NewAmsterdam Pharma Price Performance

Shares of NAMS traded up $0.26 during trading hours on Thursday, hitting $25.96. The company’s stock had a trading volume of 726,448 shares, compared to its average volume of 379,852. The business has a 50 day simple moving average of $22.39 and a two-hundred day simple moving average of $19.30. NewAmsterdam Pharma has a 52-week low of $11.57 and a 52-week high of $27.29.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in shares of NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after purchasing an additional 1,399 shares in the last quarter. Banque Cantonale Vaudoise bought a new position in NewAmsterdam Pharma in the 2nd quarter worth about $38,000. Quarry LP grew its holdings in NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after buying an additional 6,247 shares in the last quarter. Barclays PLC increased its position in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares during the period. Finally, Bellevue Group AG bought a new stake in shares of NewAmsterdam Pharma during the third quarter valued at about $128,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NAMS has been the subject of several research analyst reports. HC Wainwright began coverage on NewAmsterdam Pharma in a research report on Monday. They set a “buy” rating and a $48.00 target price for the company. Royal Bank of Canada restated an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Piper Sandler reissued an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a report on Wednesday, December 11th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma has a consensus rating of “Buy” and a consensus price target of $38.17.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.